We agree with the writer's comments that ''AMACR is an emerging diagnostic and prognostic tool in systemic malignancies''. The writer mentioned hepatocellular and gastric cancers. In our paper, we focused on the utility of the marker in distinguishing between benign and malignant prostate disorders. Obviously, as the writer pointed out, more large-scale studies are required to confirm these initial observations on the utility of AMACR as a diagnostic and prognostic tool in prostate, urothelial, gastric, hepatocellular, colorectal and possibly other neoplasms.
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